Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

The developing role of transition to practice programs for newly graduated mental health nurses.

Procter N, Beutel J, Deuter K, Curren D, de Crespigny C, Simon M.

Int J Nurs Pract. 2011 Jun;17(3):254-61. doi: 10.1111/j.1440-172X.2011.01932.x. Review.

PMID:
21605265
2.

Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients.

Beutel J, Wegner J, Wegner R, Ziemssen F, Nassar K, Rohrbach JM, Hilgers RD, Lüke M, Grisanti S.

Curr Eye Res. 2009 Nov;34(11):1004-9. doi: 10.3109/02713680903262205.

PMID:
19958117
3.

Current and future therapies for age-related macular degeneration.

Beutel J, Rudolf M, Grisanti S.

Expert Opin Emerg Drugs. 2009 Jun;14(2):341-62. doi: 10.1517/14728210902824141 . Review.

PMID:
19392638
4.

Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).

Lüke M, Ziemssen F, Völker M, Altpeter E, Beutel J, Besch D, Bartz-Schmidt KU, Gelisken F.

Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):745-54. doi: 10.1007/s00417-009-1050-5. Epub 2009 Feb 12.

PMID:
19214552
5.

Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results.

Beutel J, Ziemssen F, Lüke M, Partsch M, Bartz-Schmidt KU; Bevacizumab Study Group, Gelisken F.

Int Ophthalmol. 2010 Feb;30(1):15-22. doi: 10.1007/s10792-008-9282-7. Epub 2008 Dec 20.

PMID:
19099203
6.

[Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model].

Beutel J, Lüke M, Bartz-Schmidt KU, Grisanti S.

Ophthalmologe. 2009 Oct;106(10):893-8. doi: 10.1007/s00347-008-1847-3. German.

PMID:
18830601
7.

Treatment of chronic ocular hypotony with intraocular application of sodium hyaluronate.

Küçükerdönmez C, Beutel J, Bartz-Schmidt KU, Gelisken F.

Br J Ophthalmol. 2009 Feb;93(2):235-9. doi: 10.1136/bjo.2008.143834. Epub 2008 Oct 1.

PMID:
18829633
8.

Bevacizumab as adjuvant for neovascular glaucoma.

Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E; Bevacizumab Study Group, Grisanti S.

Acta Ophthalmol. 2010 Feb;88(1):103-9. doi: 10.1111/j.1755-3768.2008.01355.x. Epub 2009 Sep 20.

PMID:
18811641
9.

Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma.

Ulmer A, Beutel J, Süsskind D, Hilgers RD, Ziemssen F, Lüke M, Röcken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU, Grisanti S.

Clin Cancer Res. 2008 Jul 15;14(14):4469-74. doi: 10.1158/1078-0432.CCR-08-0012.

10.

The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina.

Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P.

Exp Eye Res. 2008 Jul;87(1):22-9. doi: 10.1016/j.exer.2008.04.005. Epub 2008 Apr 23.

PMID:
18514644
11.

Electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina.

Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Jaissle GB, Bartz-Schmidt KU, Szurman P.

Graefes Arch Clin Exp Ophthalmol. 2008 Jun;246(6):817-22. doi: 10.1007/s00417-007-0761-8. Epub 2008 Jan 16.

PMID:
18197412
12.

An action research protocol to strengthen system-wide inter-professional learning and practice [LP0775514].

Braithwaite J, Westbrook JI, Foxwell AR, Boyce R, Devinney T, Budge M, Murphy K, Ryall MA, Beutel J, Vanderheide R, Renton E, Travaglia J, Stone J, Barnard A, Greenfield D, Corbett A, Nugus P, Clay-Williams R.

BMC Health Serv Res. 2007 Sep 13;7:144.

13.

Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.

Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group.

Int Ophthalmol. 2008 Apr;28(2):101-9. Epub 2007 Jul 20.

PMID:
17634860
14.

The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.

Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group.

Br J Ophthalmol. 2007 Aug;91(8):1077-82. Epub 2007 Mar 23.

15.

Internal limiting membrane peeling with indocyanine green or trypan blue in macular hole surgery: a randomized trial.

Beutel J, Dahmen G, Ziegler A, Hoerauf H.

Arch Ophthalmol. 2007 Mar;125(3):326-32.

PMID:
17353402
16.

Inner limiting membrane as membranous support in RPE sheet-transplantation.

Beutel J, Greulich L, Lüke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S.

Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1469-73. Epub 2007 Mar 7.

PMID:
17342501
17.

Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model.

Beutel J, Schroder C, von Hof K, Rades D, Kosmehl H, Wedel T, Sieg P, Geerling G, Hakim SG.

Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1347-55. Epub 2007 Feb 21.

PMID:
17318564
18.

[Squamous cell carcinoma of the conjunctiva with orbital invasion: orbital exenteration or minimally invasive procedure?].

Beutel J, Sommer K, Gottschalk S, Neppert B, Geerling G.

Ophthalmologe. 2006 Aug;103(8):693-7. German.

PMID:
16819663
19.

Nurse managers in Australia: mentoring, leadership and career progression.

Moran P, Duffield C, Beutel J, Bunt S, Thornton A, Wills J, Cahill P, Franks H.

Can J Nurs Leadersh. 2002 May-Jun;15(2):14-20.

PMID:
12102238
20.

Profile of first-line nurse managers in New South Wales, Australia, in the 1990s.

Duffield C, Moran P, Beutel J, Bunt S, Thornton A, Wills J, Cahill P, Franks H.

J Adv Nurs. 2001 Dec;36(6):785-93.

PMID:
11903708
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk